Microarray Scanners Market Trends

The rising prevalence of chronic diseases is a significant driver for market. These diseases often exhibit significant heterogeneity among patients, requiring personalized treatment approaches tailored to individual genetic and molecular profiles.

• Chronic diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders are complex and multifactorial in nature. Microarray technology enables researchers to analyze the expression patterns of thousands of genes simultaneously, allowing for a better understanding of disease mechanisms and the discovery of potential biomarkers associated with disease onset, progression, and response to treatment.
  
• For instance, according to the International Diabetes federation (IDF), 537 million adults (1 in 10) were living with diabetes in 2022. This number is expected rise to 643 million by 2030 and 783 million by 2045.
  
• Similarly, as per National Institutes of Health, cancer has accounted for approximately 9.6 to 10 million deaths across the world in 2023. This is equivalent to around 26,300 deaths every day due to cancer.
  
• Microarray technology allows for the detection of subtle changes in gene expression patterns or DNA alterations associated with early-stage disease development. By identifying molecular signatures indicative of disease onset or progression, these scanners enable earlier intervention and implementation of preventive measures, potentially reducing morbidity and mortality rates associated with chronic diseases, thereby increasing the growth of the market.